Revolution Contraceptives

What Revolution Contraceptives does

NEXT Life Sciences, Inc. is a privately held, US-incorporated reproductive healthcare company that positions itself as serving couples seeking contraception and family planning solutions. Its corporate website carries the descriptor "Modern Reproductive Healthcare" and the tagline "Helping couples come together," with the primary customer persona articulated as couples needing reproductive healthcare. The company operates an associated consumer-facing brand, "Plan A For Men," hosted at planaformen.com, which is referenced as the company's solutions platform ("OUR SOLUTIONS" links to planaformen.com), suggesting a male-contraception product focus. The corporate site is a minimal Squarespace landing page with sections for Home, About/Team, News (linking to planaformen.com/news), Contact, and an email newsletter signup collecting first name, last name, and email — no e-commerce, product catalog, pricing, or distribution information is disclosed on the available source material.

The company's business model, product portfolio specifics, underlying technology, pricing, and revenue mechanics are not disclosed in the available source material. The homepage carries a regulatory disclaimer ("These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease"), which indicates the company is operating in a regulated medical product / device / pharmaceutical domain where FDA pathways are relevant — consistent with a contraceptive product in development or early commercialization. No headcount, funding history, ownership structure, leadership team, patents, partnerships, or named customers are disclosed. Operating geography, distribution channels, and revenue are all unstated. The single observable go-to-market motion is a top-of-funnel email newsletter capture on the corporate site, pointing to a direct-to-consumer awareness-building posture typical of an early-stage, pre-commercialization healthcare company.

Name

Revolution Contraceptives

Legal name

NEXT Life Sciences, Inc.

Website

https://vasalgel.org

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

NEXT Life Sciences is a privately held US reproductive healthcare company targeting couples seeking contraception and family planning, operating through a corporate website and the associated consumer brand "Plan A For Men" (planaformen.com), with no disclosed products, pricing, or revenue.

Ownership category

akta.pro rank

Product category

Reproductive Healthcare

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Reproductive healthcare products
• Contraceptive solutions
• Male contraception
• Family planning products
• Hormonal contraceptives

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Marketing channels1 record

Core offering

Revolution Contraceptives (operating as NEXT Life Sciences, Inc.) is a modern reproductive healthcare company that provides contraception and family planning solutions for couples, with its associated brand platform "Plan A For Men" (planaformen.com) suggesting a focus on male contraceptive products. The company positions itself around the tagline "Helping couples come together." Specific product SKUs, formulations, and technical product details are not publicly disclosed on the available source material.

Product overview

NEXT Life Sciences is a modern reproductive healthcare company focused on helping couples. Based on the homepage content, the company offers solutions through its associated brand platform (planaformen.com). The specific products and services portfolio details are not available on this source page, as the homepage primarily serves as a corporate landing page with team information and newsletter signup functionality.

Differentiator

Problem solved

Functional benefit

Products and services

• Plan A For Men

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves4 records

Expansion highlights3 records

Direct peers

• YourChoice Therapeutics: YourChoice Therapeutics is developing a non-hormonal male contraceptive (YCT-529, a retinoic-acid receptor inhibitor). Same target indication (reversible male contraception), same customer (couples), and same competitive set.
• Veru Inc. Veru is a pharma company with reproductive-health and contraceptive products (e.g., the FC2 female condom and the ENTADFI franchise), comparable as a small-cap, product-focused reproductive-health pharma peer addressing similar provider channels.
• Contraline: Contraline is developing a long-acting, reversible male contraceptive (ADAM hydrogel), directly comparable to a Plan A-style non-hormonal reversible male contraceptive in clinical-stage development. Competes in the same category with the same target end-user.
• Eppin Pharma: Eppin Pharma is developing a non-hormonal, reversible male contraceptive targeting the same unmet need that Revolution Contraceptives addresses. Closest comparable by indication, mechanism (non-hormonal), and target customer (couples seeking reversible male contraception).
• Evofem Biosciences: Evofem commercializes Phexxi, a non-hormonal contraceptive for women, and is a directly comparable contraceptive-product peer in terms of regulatory pathway, prescriber model, and the non-hormonal reproductive-health positioning that distinguishes Revolution Contraceptives.

Broad incumbents

• Organon & Co. Organon is a global women's health and reproductive-health pharmaceutical incumbent with established commercial infrastructure, hormonal contraceptives, and fertility brands. Comparable as the broad incumbent a successful male contraceptive would ultimately challenge or partner with.
• CooperSurgical: CooperSurgical is a large medical-device and fertility-services incumbent serving reproductive-health providers and patients. Comparable as a broad incumbent with established OB/GYN and fertility channels that a male contraceptive launch would need to access.

Others

• Population Council: Population Council is a nonprofit research organization that has historically led development of new contraceptive technologies (including longer-acting methods). Comparable as a developer/funder in the same R&D ecosystem and as a likely competitor or partner for early-stage contraceptive IP.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/vasalgel
• Facebookfacebook.com/Vasalgel

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revolution Contraceptives